摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-溴-3-碘-吡唑并[1,5-a]嘧啶 | 1109284-33-4

中文名称
6-溴-3-碘-吡唑并[1,5-a]嘧啶
中文别名
6-溴-3-碘-吡唑并[1,5-A]嘧啶;6-溴-3-碘-吡唑并1,5-A嘧啶
英文名称
6-bromo-3-iodopyrazolo[1,5-a]pyrimidine
英文别名
——
6-溴-3-碘-吡唑并[1,5-a]嘧啶化学式
CAS
1109284-33-4
化学式
C6H3BrIN3
mdl
——
分子量
323.918
InChiKey
YYRFAUZQNJMKHU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    2?+-.0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    11
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    30.2
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 危险性防范说明:
    P261,P305+P351+P338
  • 危险性描述:
    H302,H315,H319,H335

SDS

SDS:339552ca06989a75caf6732965c54a60
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: 6-Bromo-3-iodopyrazolo[1,5-a]pyrimidine
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: 6-Bromo-3-iodopyrazolo[1,5-a]pyrimidine
CAS number: 1109284-33-4

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H3BrIN3
Molecular weight: 323.9

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide, hydrogen Iodide.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    6-溴-3-碘-吡唑并[1,5-a]嘧啶四(三苯基膦)钯 、 sodium carbonate 作用下, 以 1,4-二氧六环 为溶剂, 生成 methyl 4-(6-(1-methyl-1H-pyrazol-4-yl)pyrazolo[1,5-a]pyrimidin-3-yl)thiophene-2-carboxylate
    参考文献:
    名称:
    Optimization of microtubule affinity regulating kinase (MARK) inhibitors with improved physical properties
    摘要:
    Inhibition of microtubule affinity regulating kinase (MARK) represents a potentially attractive means of arresting neurofibrillary tangle pathology in Alzheimer's disease. This manuscript outlines efforts to optimize a pyrazolopyrimidine series of MARK inhibitors by focusing on improvements in potency, physical properties and attributes amenable to CNS penetration. A unique cylcyclohexyldiamine scaffold was identified that led to remarkable improvements in potency, opening up opportunities to reduce MW, Pgp efflux and improve pharmacokinetic properties while also conferring improved solubility. (C) 2016 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2016.02.003
  • 作为产物:
    描述:
    6-溴-吡唑[1,5-a]咪唑 在 ammonium cerium (IV) nitrate 、 作用下, 以 乙腈 为溶剂, 反应 24.0h, 生成 6-溴-3-碘-吡唑并[1,5-a]嘧啶
    参考文献:
    名称:
    [EN] PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES
    [FR] DÉRIVÉS DE LA PYRAZOLO[1,5-A]PYRIMIDINE
    摘要:
    以下式(I)的化合物是微管亲和调节激酶的抑制剂,因此可用于治疗与tau蛋白过度磷酸化相关的神经退行性疾病。
    公开号:
    WO2009014620A1
点击查看最新优质反应信息

文献信息

  • [EN] PYRAZOLO[1,5-A]PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE LA PYRAZOLO[1,5-A]PYRIMIDINE
    申请人:MERCK & CO INC
    公开号:WO2009014620A1
    公开(公告)日:2009-01-29
    Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.
    以下式(I)的化合物是微管亲和调节激酶的抑制剂,因此可用于治疗与tau蛋白过度磷酸化相关的神经退行性疾病。
  • 一种吡唑并嘧啶化合物及其用途和发光器件
    申请人:上海道亦化工科技有限公司
    公开号:CN108484608A
    公开(公告)日:2018-09-04
    本发明提供了一种吡唑并嘧啶化合物,具有如下结构式:该吡唑并嘧啶化合物具有较好的热稳定性、高发光效率、高发光纯度,可以应用于有机电致发光器件、太阳能电池、有机薄膜晶体管或有机光感受器领域。本发明还提供了一种有机电致发光器件,该器件包含阳极、阴极和有机层,有机层包含发光层、空穴注入层、空穴传输层、空穴阻挡层、电子注入层、电子传输层中的至少一层,有机层中至少有一层含有如结构式I的吡唑并嘧啶化合物,采用吡唑并嘧啶化合物制作的有机电致发光器件具有高的效率和光纯度。
  • Pyrazolo[1,5-a]pyrimidine derivatives
    申请人:Stanton Matthew G.
    公开号:US08461162B2
    公开(公告)日:2013-06-11
    Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.
    以下化合物(I)的结构式是微管亲和力调节激酶的抑制剂,因此可用于治疗与tau超磷酸化相关的神经退行性疾病。
  • PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES
    申请人:Stanton Matthew G.
    公开号:US20100305091A1
    公开(公告)日:2010-12-02
    Compounds of the following formula (I) are inhibitors of microtubule affinity regulating kinase, and hence find use in the treatment of neurodegenerative diseases associated with hyperphosphorylation of tau.
    以下公式(I)的化合物是微管亲和力调节激酶的抑制剂,因此可用于治疗与tau超磷酸化相关的神经退行性疾病。
  • BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF
    申请人:SUZHOU KEEN THERAPEUTICS CO., LTD.
    公开号:WO2023241620A1
    公开(公告)日:2023-12-21
    Provided are compounds, compositions, methods, use for preventing or treating various conditions, disorders or diseases. In some embodiments, a condition, disorder or disease is cancer.
    本文提供了用于预防或治疗各种病症、紊乱或疾病的化合物、组合物、方法和用途。在某些实施方案中,病症、紊乱或疾病是癌症。
查看更多

同类化合物

阿拉格列汀 间型霉素环-3',5'-单磷酸酯 西地那非杂质 苯,[(1-甲基环戊基)硫代]- 苄基-(6-氯-1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 甲基-(6-甲基磺酰基-1(2)H-吡唑并[3,4-d]嘧啶-4-基)-胺 环己基-(1-甲基-1H-吡唑并[3,4-d]嘧啶-4-基)-胺 氮杂环庚-1-基-[7-氯-4-噻吩-2-基-2-(三氟甲基)-1,5,9-三氮杂双环[4.3.0]壬-2,4,6,8-四烯-8-基]甲酮 异丙基 4-(1-甲基-7-氧代-3-丙基-6,7-二氢-1H-吡唑并[4,3-d]嘧啶-5-基)噻吩-2-基磺酰基氨基甲酸酯 吡啶-2-基-[7-吡啶-4-基-吡唑[1,5-a]嘧啶-3-基]甲酮 吡唑并[2,3-a]嘧啶 吡唑并[1,5-a]嘧啶-7-胺 吡唑并[1,5-a]嘧啶-7(1h)-酮 吡唑并[1,5-a]嘧啶-6-醇 吡唑并[1,5-a]嘧啶-6-羧酸乙酯 吡唑并[1,5-a]嘧啶-6-羧酸 吡唑并[1,5-a]嘧啶-5-羧酸 吡唑并[1,5-a]嘧啶-3-胺盐酸盐(1:1) 吡唑并[1,5-a]嘧啶-3-胺;三氟乙酸 吡唑并[1,5-a]嘧啶-3-羰酰氯 吡唑并[1,5-a]嘧啶-3-羧酸乙酯 吡唑并[1,5-a]嘧啶-3-羧酸 吡唑并[1,5-a]嘧啶-3-磺酰胺 吡唑并[1,5-a]嘧啶-3-甲酰胺 吡唑并[1,5-a]嘧啶-3-甲腈 吡唑并[1,5-a]嘧啶-2-羧酸乙酯 吡唑并[1,5-a]嘧啶-2-羧酸 吡唑并[1,5-a]嘧啶,2-甲基-6-(1-甲基乙基)- 吡唑并[1,5-a]嘧啶,2-溴-5,7-二甲基- 吡唑并[1,5-A]嘧啶-5-胺 吡唑并[1,5-A]嘧啶-5(4H)-酮 吡唑并[1,5-A]嘧啶-3-甲醛 吡唑[1,5-A]嘧啶-5-羧酸甲酯 吡唑[1,5-A]嘧啶-5,7(4H,6H)-二酮 双氯地那非 别嘌醇 别嘌呤醇D2 二硫代乙基碳萘甲醚 二硫代-脱甲基-昔多芬 乙基7-甲基吡唑并[1,5-a]嘧啶-6-羧酸酯 [1,2]恶唑并[4,3-e]吡唑并[1,5-A]嘧啶 [(2S,5R)-5-(4-氨基-1H-吡唑并[3,4-d]嘧啶-1-基)四氢呋喃-2-基]甲醇 VEGFR2激酶抑制剂IV N5-(6-氨基己基)-N7-苄基-3-异丙基吡唑并[1,5-a]嘧啶-5,7-二胺 N5-(1-环庚基-1H-吡唑并[3,4-d]嘧啶-6-基)吡啶-2,5-二胺 N3-(4-氟苯基)-1H-吡唑并[3,4-D]嘧啶-3,4-二胺 N-苄基-6-氯-1H-吡唑并[3,4-d]嘧啶-4-胺 N-苄基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-甲基-1H-吡唑并[3,4-d]嘧啶-4-胺 N-[2-(3-氨基-3-氧代丙氧基)乙基]-6-(4-溴苄基)吡唑并[1,5-a]嘧啶-3-甲酰胺